GLGuangquan Liu

Guangquan Liu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Guangquan Liu has a total of 9 co-authors. Here are the top co-authors by number of shared publications:

  • Fang Teng

    Department of Gynecology, Women’s Hospital of Nanjing Medical University, Nanjing Women and Children’s Healthcare Hospital, Nanjing, 210000, People’s Republic of China

    1 shared publication
  • Hanzi Xu

    Department of Radiation Oncology, The Affiliated Cancer Hospital of Nanjing Medical University & Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research, Nanjing, China

    1 shared publication
  • Juan Xu

    Department of Gynecology, Women’s Hospital of Nanjing Medical University (Nanjing Women and Children’s Healthcare Hospital), Nanjing, China

    1 shared publication
  • Lili Ge

    Henan Key Laboratory of Children's Genetics and Metabolic Diseases, Children's Hospital Affiliated to Zhengzhou University, Henan Children's Hospital, Zhengzhou Children's Hospital, Zhengzhou 450018, China

    1 shared publication
  • Xiyi Chen

    Department of Gynecology Women's Hospital of Nanjing Medical University (Nanjing Maternity and Child Health Care Hospital) Nanjing China

    1 shared publication
  • Xuemei Jia

    Department of Gynecology Women's Hospital of Nanjing Medical University Nanjing Women and Children's Healthcare Hospital Nanjing Medical University Nanjing 210004 P. R. China

    1 shared publication

Latest Publications

  • Open Access

    Plasma circRNA microarray profiling identifies novel circRNA biomarkers for the diagnosis of ovarian cancer

    by Lili Ge, Yu Sun, Yaqian Shi, Guangquan Liu, Fang Teng, Zhe Geng, Xiyi Chen, Hanzi Xu, Juan Xu, Xuemei Jia

    Background: Circular RNA (circRNA), a class of RNA with a covalent closed circular structure that widely existed in serum and plasma, has been considered an ideal liquid biopsy marker in many diseases. In this study, we employed microarray and qRT-PCR to evaluate the potential circulating circRNAs with diagnostic efficacy in ovarian cancer. Methods: We used microarray to explore the circRNA expression profile in ovarian cancer patients’ plasma and quantitative real-time (qRT)-PCR approach to assessing the candidate circRNA’s expression. Then the receiver operating characteristic (ROC) curve was employed to analyze the diagnostic values of candidate circRNAs. The diagnostic model circCOMBO was a combination of hsa_circ_0003972 and hsa_circ_0007288 built by binary logistic regression. Then bioinformatic tools were used to predict their potential mechanisms. Results: Hsa_circ_0003972 and hsa_circ_0007288 were downregulated in ovarian cancer patients’ plasma, tissues, and cell lines, comparing with the controls. Hsa_circ_0003972 and hsa_circ_0007288 exhibited diagnostic values with the Area Under Curve (AUC) of 0.724 and 0.790, respectively. circCOMBO showed a better diagnostic utility (AUC: 0.781), while the combination of circCOMBO and carbohydrate antigen 125 (CA125) showed the highest diagnostic value (AUC: 0.923). Furthermore, the higher expression level of hsa_circ_0007288 in both plasma and ovarian cancer tissues was associated with lower lymph node metastasis potential in ovarian cancer. Conclusions: Our results revealed that hsa_circ_0003972 and hsa_circ_0007288 may serve as novel circulating biomarkers for ovarian cancer diagnosis.